Status:
COMPLETED
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
SARS CoV 2 Infection
Eligibility:
All Genders
Brief Summary
Up to now, Corona Virus Disease 2019 (COVID-19) continues to spread rapidly around the world. From the beginning of the epidemic to the present, severe acute respiratory syndrome coronavirus 2 (SARS-C...
Detailed Description
In this study, through follow-up of SARS-COV-2 Delta infection patients in Xi 'an, Shaanxi Province, China, exploring the effects of vaccination on nucleic acid turning negative, clinical characterist...
Eligibility Criteria
Inclusion
- Diagnosed with SARS-COV-2 Delta infection
- Clear vaccination information
- Plasma viral load measurements within 24 hours of admission to the hospital
- Performing continuous plasma viral load measurements
- Obtaining informed consent
Exclusion
- Pregnant women
- Clinical diagnosis of organ dysfunction or failure before infection
- Long-term use of immunosuppressants or immunodeficiency patients
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2022
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05244330
Start Date
December 15 2021
End Date
January 15 2022
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xian JiaotongUniversity
Xi'an, Shaanxi, China, 710061